The purpose of this study was to estimate the costs and benefits of the use of recombinant human erythropoietin (rHuEpo) in the chronic renal failure anaemia. Although experience in the use of rHuEpo is growing, evidence from controlled studies, addressed toward its impact on patient survival and the importance of side effects, is not available. Consequently, a costmodelling approach was used on secondary data collected from a variety of sources. The cost of rHuEpo treatment in various countries per patient per year ranged from 3,681$ AUS to 10,000$ CAN. Because rHuEpo is not a life-saving intervention, its benefits are measured in terms of improved quality of life, with a very high cost-benefit ratio. At current prices rHuEpo can only produce a competitive cost per QALY for patients with serious incapacity as a result of anaemia.
|Number of pages||5|
|Journal||Giornale Italiano di Farmacia Clinica|
|Publication status||Published - 1993|
ASJC Scopus subject areas
- Pharmacology (medical)